BTIG Cuts Intuitive Surgical (ISRG) Price Target to $454

BTIG has reiterated its Buy rating on Intuitive Surgical, adjusting its price target to $454 on October 12, 2026, a 5.95% upside from the current price.

By EarningsIQ Research Desk · Published Oct 16, 2026, 1:59 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

BTIG cut its price target on Intuitive Surgical, Inc. ($ISRG) to $454 from $469 on October 12, 2026, and rates the stock "Buy".

Since the rating, $ISRG is down 0.2% to date (from the $427.64 close on Oct 12, 2026).

ISRG Intuitive Surgical, Inc.

$426.70 -24.07% year to date

Daily close · Oct 16, 2026

Key Points

BTIG has maintained its Buy rating on Intuitive Surgical, lowering its price target from $469 to $454.
BTIG's $454 price target implies 5.95% upside from Intuitive Surgical, Inc.'s ($ISRG) current $428.52 share price.
As of October 16, 2026, ISRG trades recently around $428.52, which is about 10.5% below the mean analyst target of $478.53.
The next earnings report for Intuitive Surgical is set for October 20, 2026.

Get $ISRG trade alerts by text

We text you when insiders, Congress or big funds trade $ISRG. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Intuitive Surgical, Inc. alert may contain errors. Disclosures

BTIG has reiterated its Buy rating on Intuitive Surgical, Inc. (ISRG) and adjusted its price target to $454 on October 12, 2026. This is a decrease from the previous target of $469. The firm believes in the company's potential despite the lower target.

Other Institutional Activity in Intuitive Surgical

Several other institutional investors have made adjustments to their positions in Intuitive Surgical. Blackrock Inc. trimmed its stake by 51,129 shares, ending with 30,024,648 shares valued at about $12.8 billion. Vanguard Capital Management LLC grew its holdings by 50,777 shares, resulting in a total of 23,131,099 shares worth approximately $9.87 billion. State Street Corporation increased its position by 215,526 shares, bringing its total to 16,063,040 shares valued at around $6.85 billion. Invesco Ltd. also added 653,500 shares, ending with 11,843,563 shares worth about $5.05 billion, while Price (T. Rowe) Associates Inc. reduced its stake by 1,263,250 shares, holding 11,256,570 shares valued at $4.8 billion.

Intuitive Surgical, Inc. Stock Up 2.0%

As of October 16, 2026, ISRG trades around $428.52, which is 10.5% below the analysts' mean target of $478.53. The stock is currently above its 52-week low of $328.57 by about 30.4%, but it remains 29% below its 52-week high of $603.88. It also trades above its 50-day moving average by 9.7%, but below its 200-day average by 2.7%.

12-month forecast

$ISRG price target

Intuitive Surgical, Inc. daily closes and this analyst's $454 target. Not advice.

Recent Earnings

Intuitive Surgical reported trailing twelve-month revenue of approximately $11.03 billion, reflecting a year-over-year growth of 18.5%. The company has an EPS of $8.72 and a net margin of 28.4%. The next earnings report is expected on October 20, 2026.

Insider Buying and Selling at Intuitive Surgical, Inc.

Insider transactions at Intuitive Surgical show several sales by Officer Mark Preston Brosius, who sold 154 shares on August 21, 2026, 69 shares on September 9, 2026, and 48 shares on September 11, 2026. Additionally, Officer Fredrik Widman sold 1,089 shares on September 15, 2026, at an average price of $374.44.

Analysts Set New Price Targets

On October 12, 2026, BTIG reiterated its Buy rating on ISRG with a new price target of $454, down from $469. This reflects a cautious outlook amid current market conditions. The consensus among analysts remains positive, with a mean target price of $478.53 from 30 opinions.

About Intuitive Surgical

Intuitive Surgical, Inc. develops and sells robotic-assisted surgical systems that help doctors perform minimally invasive surgeries. The company is a leader in the healthcare technology sector, focusing on enhancing surgical care quality and access. Its products are used worldwide, making it a key player in the medical instruments and supplies industry.

Bottom Line

Investors should keep an eye on the upcoming earnings report scheduled for October 20, 2026. With BTIG maintaining a Buy rating and a revised target, the market will watch how Intuitive Surgical responds to current industry dynamics.